2 active not recruiting, 2 recruiting, 1 completed. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Active not recruiting 2, Recruiting 2, Completed 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow Solitary Fibrous Tumors: new trials by email Literature Review of Solitary Fibrous Tumors trials Research Report on Solitary Fibrous Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors OKN4395, Pembrolizumab, Fasting - Solid Tumours, Sarcoma | Phase 1 | Recruiting | Epkin | 146 | 2025-01-23 | 2026-06-11 |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Oral repotrectinib (TPX-0005) - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Turning Point Therapeutics, Inc. | 75 | 2020-03-12 | 2026-09-25 |
| Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin - Soft Tissue Sarcoma, Bone Sarcoma | Phase 1 / Phase 2 | Completed | Grupo Espanol de Investigacion en Sarcomas | 197 | 2017-05-31 | 2024-08-13 |
| Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Cediranib Maleate, Cisplatin, Laboratory Biomarker Analysis - Epithelioid Mesothelioma, Pleural Malignant Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 117 | 2010-03-15 | 2026-10-22 |
Sarcoma (4) · Colorectal Neoplasms (2) · Histiocytoma, Malignant Fibrous (2) · Leiomyosarcoma (2) · Stomach Neoplasms (2) · Adrenal Gland Neoplasms (1) · Anus Neoplasms (1) · Bone Neoplasms (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Medullary (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Connective Tissue (5) · Neoplasms, Connective and Soft Tissue (5) · Neoplasms, Fibrous Tissue (5) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Carcinoma (2) · Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2)
Cisplatin (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Angptl4 protein, mouse (1) · Capsules (1) · Dacarbazine (1) · Doxorubicin (1) · Epirubicin (1) · FAPI-46 (1) · Famotidine (1) · Fluorodeoxyglucose F18 (1) · Histamine H2 Antagonists (1) · Ifosfamide (1) · Magnetic Resonance Spectroscopy (1) · Methotrexate (1) · Nivolumab (1)
Epkin (1) · Grupo Espanol de Investigacion en Sarcomas (1) · Jonsson Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1) · Turning Point Therapeutics, Inc. (1)
United States (4) · United Kingdom (3) · Australia (2) · Italy (2) · Spain (2) · Canada (1) · Denmark (1) · France (1) · Singapore (1) · South Korea (1) · Taiwan (1)
Alba Rubio (1) · Anne S Tsao (1) · Antonio Casado (1) · Claudia Valverde (1) · Cristina Mata (1) · Emanuela Palmerini (1) · Giovanni Grignani (1) · Irene Carrasco (1)
PMID 31386610, PMID 31401903, PMID 33203665, PMID 34814185, PMID 39356980, PMID 41836677
2023 (1), U10CA032102 (1), U10CA180830 (1), U10CA180888 (1)